COMMUNIQUÉS West-GlobeNewswire

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

16/05/2024 - 14:00

SARASOTA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced an update on [...]

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

16/05/2024 - 13:30

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long- [...]

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16/05/2024 - 12:00

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib [...]

South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports

16/05/2024 - 12:00

SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications Publication introduces SRP-001 as a safer alternative to existing pain medications SRP- [...]

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

16/05/2024 - 12:00

Sol-Gel to receive a total consideration of up to US$15 million, out of which US$10 million will be paid as upfront and regulatory milestones NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, [...]

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

16/05/2024 - 11:27

Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance threshold Settlement of the shares tendered during the initial acceptance [...]

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder)

16/05/2024 - 11:09

The event will take place on Thursday, 6 June 2024 at Coloplast’s Headquarters Holtedam 3, 3050 Humlebaek, Denmark from 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity [...]

Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation

16/05/2024 - 09:04

Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces today it has [...]

L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations

16/05/2024 - 09:04

Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et inflammatoires, [...]

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants

16/05/2024 - 08:00

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid [...]

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

16/05/2024 - 07:15

Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]

Zealand Pharma Announces Financial Results for the First Quarter of 2024

16/05/2024 - 07:00

Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across [...]

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

16/05/2024 - 07:00

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100% of CT-388 treated [...]

HEPHAISTOS secures €10.3 M to reach the clinical stage

16/05/2024 - 06:00

PR: HEPHAISTOS secures €10.3 M to reach the clinical stage HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led [...]

HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique

16/05/2024 - 06:00

Communiqué : HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique HEPHAISTOS-Pharma accueille Elaia qui boucle son tour d’amorçage, sécurisant ainsi un total de 10,3 millions d'euros, entre financements dilutifs et [...]

CloudMD Reports 2023 Results for the Full Year and Fourth Quarter

16/05/2024 - 05:16

Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates. Q4 2023 gross profit margin 1 of 39.7% was [...]

Assure & Danam Postpone Corporate Update Call & Webcast Scheduled for May 16

16/05/2024 - 02:50

DENVER, May 15, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that the [...]

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

16/05/2024 - 02:00

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]

ONWARD® Medical organise un webinaire pour présenter l’état des lieux de ses activités du premier trimestre 2024

16/05/2024 - 00:43

EINDHOVEN, Pays-Bas, 16 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et [...]